Meda Biotech, LLC was founded in 2003 on the strength of a conviction that a new concept of Hybrid drugs as solubility solution for insoluble drugs discovered by Dr. Mewa Singh, Nano. A Hybrid-Nanoengineering™, could have real therapeutic value for patients. That belief gave birth to a process of continual discovery and innovation, allowing it to bring many innovative medicines. Since 2002, Meda Biotech has been working to commercialize a technology that could make, especially the cancer, pain and inflammation, treatment more effective and less harmful to patients.

Meda Biotech is a clinical-stage biopharmaceutical company developing a new class of Hybrid- Nanoengineering™ platform enables the design, engineering and manufacturing of Hybrid water soluble drugs with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
Meda Biotech is developing a pipeline of novel Hybrid drugs that hold extraordinary potential to become best-in-class drugs and improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular and GI disorders. Meda’s lead product candidate, Mewa001 (Aspirin) is currently in Phase 1 clinical testing in cancer patients for pain and inflammation. Meda also develops Hybrid water soluble drugs in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential. Meda is developing its own bank of water soluble hybrid to enhance the performance of important existing drug products.Our company has developed a method to encasing the toxic drug inside a less toxic drug and build a hybrid molecule that then can inject into a patient. These hybrid drugs are suppose to be much more effective to treat the patients.

At the same time our hybrid makes the water insoluble drugs into water soluble. In short our discovery leads to a new generation of hybrid formulation of two drugs to attack the disease more aggressive and safely. Both the molecules have synergistic and potentiating effects on each other. A SAFE DOUBLE EDGE SWORD.Our group of researcher was really eager to discover and develop additional game changing therapeutics. At the core of Meda discovery and development team main goal of the group was to make sure the discovery should not lead to a therapy or drug which is not affordable to average person.

This notion leads to the discovery of HYBRID DRUG TECHNOLOGY from Meda Biotech.

*If you want to become a part of our mission of development and production of novel treatment, prevention and healthy style, please do contacts us at [email protected], [email protected], or [email protected].

**If any of our American fellows cannot afford to purchase our products please send us an email and we will send you the product free of cost.